Core Insights - SI-BONE, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, with a management-hosted fireside chat [1] - The company is a leader in developing technologies for surgical treatment of sacropelvic disorders, having supported over 4,900 physicians and performed over 135,000 procedures since 2009 [3] Company Overview - SI-BONE, Inc. specializes in minimally invasive SI joint surgery, having pioneered the iFuse Implant System [3] - The company has a strong clinical foundation with over 180 peer-reviewed publications, including four randomized controlled trials [3] - SI-BONE has expanded its offerings to adjacent markets, including adult deformity and pelvic trauma [3] Conference Participation - Investors can register to listen to the conference call and access a live audio webcast on the company's website [2] - The webcast will be archived for at least 90 days post-event [2]

Core Insights - SI-BONE, Inc. reported a strong financial performance in Q3 2025, with worldwide revenue growth of approximately 21% and a positive adjusted EBITDA margin of $2.3 million, indicating robust demand for its medical devices [1][7][8]. Financial Performance - Worldwide revenue reached $48.7 million, a 20.6% increase from $40.3 million in Q3 2024 [4][8]. - U.S. revenue was $46.4 million, reflecting a 21.2% increase from $38.3 million in the same period last year, driven by strong procedure demand [4][8]. - International revenue was $2.3 million, a 10.2% increase from $2.1 million in Q3 2024, attributed to the successful launch of the TORQ product in European markets [4][8]. Profitability Metrics - Gross profit for the quarter was $38.8 million, up 21.8% from $31.9 million in Q3 2024, with a gross margin of 79.8%, an improvement of 75 basis points year-over-year [5][8]. - Operating expenses increased by 11.9% to $44.2 million, primarily due to higher commercial activities and new product rollouts [6][8]. - The operating loss improved by 29.5% to $5.4 million compared to a loss of $7.6 million in Q3 2024 [6][8]. Net Loss and Cash Flow - The net loss for the quarter was $4.6 million, or $0.11 per diluted share, an improvement of 30.6% from a net loss of $6.6 million, or $0.16 per diluted share, in Q3 2024 [7][8]. - Positive cash from operating activities was reported at $2.3 million, indicating effective cash management [8]. Guidance and Future Outlook - For fiscal 2025, SI-BONE expects worldwide revenue to be between $198 million and $200 million, representing year-over-year growth of approximately 18% to 20% [10][11]. - The company anticipates a gross margin of around 79.5% for the full year 2025, reflecting continued operational efficiency [10][11]. Operational Highlights - The number of active U.S. physicians increased by 27% to 1,530, indicating growing adoption of SI-BONE's technologies [8]. - The trailing 12-month average revenue per territory rose by 16% to $2.1 million, showcasing improved sales performance [8].

Core Insights - SI-BONE, Inc. will report its financial results for Q3 2025 on November 10, 2025, after market close [1] - A conference call will be held at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results [1] Company Overview - SI-BONE is a global leader in developing technologies for surgical treatment of sacropelvic disorders, having pioneered minimally invasive SI joint surgery in 2009 with the iFuse Implant System [3] - The company has supported over 4,600 physicians in performing nearly 130,000 procedures, backed by over 175 peer-reviewed publications, including four randomized controlled trials [3] - SI-BONE has expanded its offerings to adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation, and pelvic trauma [3]

Company Participation - SI-BONE, Inc. will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 9, 2025 [1] - Management will host a fireside chat at 4:00 a.m. Pacific Time / 07:00 a.m. Eastern Time [1] Investor Information - Investors can register for the conference call via a provided link and access the live audio webcast on the company's website [2] - The webcast will be archived for at least 90 days post-event [2] Company Overview - SI-BONE is a leader in developing technologies for surgical treatment of sacropelvic disorders, having pioneered minimally invasive SI joint surgery in 2009 with the iFuse Implant System [3] - The company has supported over 4,600 physicians in nearly 130,000 procedures, backed by over 175 peer-reviewed publications including four randomized controlled trials [3] - SI-BONE has expanded its offerings to adjacent markets such as adult deformity, spinopelvic and sacropelvic fixation, and pelvic trauma [3]

Core Viewpoint - SI-BONE, Inc. is set to report its financial results for Q2 2025 on August 4, 2025, with a conference call scheduled for the same day [1]. Company Overview - SI-BONE, Inc. is a leader in developing technologies for surgical treatment of sacropelvic disorders, having pioneered minimally invasive SI joint surgery in 2009 with the iFuse Implant System [3]. - The company has supported over 4,500 physicians in performing more than 125,000 procedures, backed by over 175 peer-reviewed publications, including two randomized controlled trials [3]. - SI-BONE has expanded its offerings to adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation, and pelvic trauma [3].

Company Overview - SI-BONE, Inc. is a medical device company focused on addressing sacropelvic disorders and is recognized as a global leader in developing innovative surgical technologies [3] - The company pioneered minimally invasive SI joint surgery in 2009 with the introduction of the iFuse Implant System, supporting over 4,500 physicians and facilitating more than 120,000 procedures [3] - SI-BONE has established a strong clinical foundation with over 160 peer-reviewed publications, including two randomized controlled trials, validating the effectiveness of its technologies [3] Upcoming Event - SI-BONE will participate in the 2025 Truist Securities MedTech Conference in Boston, MA, with a fireside chat scheduled for June 17, 2025, at 10:00 a.m. Pacific Time [1] - Investors can register for the conference call and access a live audio webcast on the company's website, which will be archived for at least 90 days post-event [2]

Company Participation - SI-BONE, Inc. will participate in the 2025 Goldman Sachs 46 Global Healthcare Conference in Miami Beach, FL, hosting a fireside chat on June 10, 2025, at 8:20 a.m. Pacific Time [1] Company Overview - SI-BONE is a global leader in developing technologies for surgical treatment of sacropelvic disorders, having pioneered minimally invasive SI joint surgery in 2009 with the iFuse Implant System [3] - The company has supported over 4,500 physicians in performing more than 120,000 procedures, backed by over 160 peer-reviewed publications, including two randomized controlled trials [3] - SI-BONE has expanded its offerings to adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation, and pelvic trauma [3]